Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)

Autor: John Woolfrey, Craig Stacy Takeuchi, Arthur Plonowski, Kyoko Yamaguchi, Ron Aoyama, Byung Gyu Kim, Anagha Abhijit Joshi, Paul Foster, Sunghoon Ma, Sharmila Rajan, Tae Gon Baik, Naing Aay, Arlyn Arcalas, Charles M. Blazey, Jonah Cannoy, Peter Lamb, Isabelle Lehoux, Chris A. Buhr, Narsimha Munagala, Matthew Sangyup Lee, John M. Nuss, James W. Leahy, Jae Lee, Sergey Epshteyn, Neel Kumar Anand, Nicole Miller, Longcheng Wang, Katherine Lara, Henry Johnson
Rok vydání: 2013
Předmět:
Zdroj: Journal of Medicinal Chemistry. 56:2218-2234
ISSN: 1520-4804
0022-2623
DOI: 10.1021/jm3007933
Popis: A series of novel, highly potent, selective, and ATP-competitive mammalian target of rapamycin (mTOR) inhibitors based on a benzoxazepine scaffold have been identified. Lead optimization resulted in the discovery of inhibitors with low nanomolar activity and greater than 1000-fold selectivity over the closely related PI3K kinases. Compound 28 (XL388) inhibited cellular phosphorylation of mTOR complex 1 (p-p70S6K, pS6, and p-4E-BP1) and mTOR complex 2 (pAKT (S473)) substrates. Furthermore, this compound displayed good pharmacokinetics and oral exposure in multiple species with moderate bioavailability. Oral administration of compound 28 to athymic nude mice implanted with human tumor xenografts afforded significant and dose-dependent antitumor activity.
Databáze: OpenAIRE